Would this be released before the conference?
Conference: Society for Immunotherapy of Cancer (SITC) Annual Meeting
Dates: November 7-11, 2018
Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
Ann: Data Presentations at Upcoming Industry Conferences, page-28
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.020(6.06%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.3¢ | 30.5¢ | $1.905M | 6.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 13147 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 101130 | 2 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
